Biotech Values

[jq1234]

JPM report was before year end 2016, number would change if YE2016 numbers were used, but overall point stands. Because of bad year for IPO from company point of view, it was a better year from investor point of view since IPO was priced much more reasonably in 2016 than recent past.

The article from FierceBiotech was bad - was going to comment on it when first posted but didn't - article written in Dec2016 citing data from summer during biotech swoon:


"it’s been pretty dismal, with a report by Renaissance Capital out in the summer showing that almost all of the biotech IPOs that priced since the first quarter have broken issue, and were trading below their offer price."